SOURCE: Callisto Pharmaceuticals, Inc.

April 26, 2005 12:00 ET

Callisto Pharmaceuticals to Present at the Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference

NEW YORK, NY -- (MARKET WIRE) -- April 26, 2005 -- Callisto Pharmaceuticals, Inc. (AMEX: KAL), a biopharmaceutical company primarily focused on the development of drugs to treat cancer and osteolytic bone disease, announced today that Dr. Donald H. Picker, Callisto Executive VP of Research & Development, will present at the Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference on Thursday, May 5, 2005, at 9:45 am, in the Salon Napoleon at The Intercontinental Hotel, 3 Rue de Castiglione, Paris France.

Dr. Picker will discuss Callisto's drug candidate for acute leukemias, Annamycin, which is planned to begin a Phase IIb clinical trial in relapsed acute myeloid leukemia (AML) patients in mid-2005. He will also discuss Callisto's orphan drug for multiple myeloma, Atiprimod, which is currently in a Phase I/IIa clinical trial in relapsed multiple myeloma patients.

About Callisto Pharmaceuticals, Inc.

Callisto is a biopharmaceutical company focused on the development of drugs to treat cancer and osteolytic bone disease. Callisto recently in-licensed Annamycin, a drug to treat leukemia, based on the drug's novel therapeutic profile, including activity against resistant diseases and significantly reduced toxicity. Callisto intends to initiate a Phase IIb clinical trial of Annamycin in relapsed acute lymphocytic leukemia patients in mid-2005. Callisto's second drug, Atiprimod, is in a Phase I/IIa clinical trial in relapsed multiple myeloma patients, and is a small-molecule, orally available drug with antiproliferative and antiangiogenic activity. Callisto also has drugs in preclinical development for melanoma, gastrointestinal inflammation, and a program focused on the development of a drug to protect against staphylococcus and streptococcus biowarfare agents. Callisto has exclusive worldwide licenses from AnorMED Inc. and M.D. Anderson Cancer Center to develop, manufacture, use and sell Atiprimod and Annamycin, respectively. For additional information, visit www.callistopharma.com.

Forward-Looking Statements

Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Callisto believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the Callisto Pharmaceuticals Annual Report on Form 10-KSB for the year ended December 31, 2003,and other periodic reports, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that products that appeared promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the risk that Callisto will not obtain approval to market its products, the risks associated with dependence upon key personnel and the need for additional financing.

Contact Information